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Background: The concept of benefit sharing has been a topical issue on the international stage for more than two
decades, gaining prominence in international law, research ethics and political philosophy. In spite of this
prominence, the concept of benefit sharing is not devoid of controversies related to its definition and justification.
This article examines the discourses and justifications of benefit sharing concept.
Discussion: We examine the discourse on benefit sharing within three main spheres; namely: common heritage of
humankind, access and use of genetic resources according to the Convention on Biological Diversity (CBD), and
international clinical research. Benefit sharing has change from a concept that is enshrined in a legally binding
regulation in the contexts of common heritage of humankind and CBD to a non-binding regulation in international
clinical research. Nonetheless, there are more ethical justifications that accentuate benefit sharing in international
clinical research than in the contexts of common heritage of humankind and the CBD.
Summary: There is a need to develop a legal framework in order to strengthen the advocacy and decisiveness of
benefit sharing practice in international health research. Based on this legal framework, research sponsors would be
required to provide a minimum set of possible benefits to participants and communities in research. Such legal
framework on benefit sharing will encourage research collaboration with local communities; and dispel mistrust
between research sponsors and host communities. However, more research is needed—drawing from other
international legal frameworks, to understand how such a legal framework on benefit sharing can be successfully
formulated in international health research.
Keywords: Benefit sharing, Research ethics, International research, Common heritage of humankind, Biodiversity,
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The concept of benefit sharing has been a topical issue on
the international stage for more than two decades, gaining
prominence in international law, research ethics and polit-
ical philosophy [1]. This prominence of benefit sharing is
mostly accompanied with controversies and contradic-
tions associated with what the concept entails and what
its definition is. Schroeder realizes this problem of defin-
ition, commenting, “for more than 15 years of entering
into international law, benefit sharing has no entry in the
Oxford English Dictionary and remains a technical word
not used in everyday academic language” [2].
Nonetheless, navigating through the contexts where
benefit sharing is prominent, we can find a definition* Correspondence: kris.dierickx@med.kuleuven.be
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distribution, and reproduction in any mediumthat suits the concept as used in that context. For ex-
ample, in the framework of the access and use of genetic
resources, benefit sharing is described as “the action of
giving a portion of advantages or profits derived from
the use of genetic resources or traditional knowledge
to resource providers in order to achieve justice in ex-
change” [1]. In the context of international research
this definition is viewed differently; it is often viewed
from the perspective of what participants and by ex-
tension the communities in developing countries ought
to receive as compensation for their participation in
research [3].
Differences in the discourses and justifications on
benefit sharing form the basis for different definitions
and also limit or broaden the concept. For example, a
compensatory justice-based discourse may limit benefit
sharing to the compensatory interaction which occursCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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while solidarity-based justifications broaden benefits to
include all human beings [3]. It is these discourses and
justifications that set the tone for this article. This article
provides an investigation into the changes in the dis-
courses and justifications of benefit sharing in order to
address the question of whether these changes affect the
present practice of benefit sharing in international re-
search. We examine these changes in three spheres.
Firstly, we assess the discourse of benefit sharing in
terms of the broader concept of the common heritage of
humankind—we assess the emergence and the ethical
disposition that benefit sharing concept is set to achieve
in the common heritage of humankind. Secondly, we as-
sess the concept in the context of the access and use of
genetic resources as outlined in the Convention on Bio-
logical Diversity (CBD). Thirdly, we examine the concept
as used in the context of international clinical research
with a focus on three formulations of benefit sharing.
This article will familiarize the reader on the main dis-
courses on benefit sharing. It is intended to contribute
to awareness among stakeholders in health research on
benefit sharing.
Discussion
We present an account of the three spheres on which
benefit sharing is commonly discussed. Based on these
spheres, we then map ethico-legal changes in benefit
sharing and assess these changes as they affect benefit
sharing in international research.
Benefit sharing within the context of the common
heritage of humankind
The notion of benefit sharing first emerged on the inter-
national platform in relation to the concept of the com-
mon heritage of humankind [4]. The common heritage of
humankind is a concept that deals with the fate of re-
sources obtained from common heritage territories (the
moon and other celestial bodies, as well as the sea and the
subsoil beneath it). The concept of the common heritage
of humankind evolved from the doctrine of res communis
which delineates that resources obtained from common
heritage territories are not meant to be monopolized, pos-
sessed or owned by individuals, communities or states; ra-
ther, the use of such resources has to be subjected to the
rights and interests of all humankind [5,6].
The relationship between the common heritage of
humankind and benefit sharing stems from one of the
cardinal elements outlined in the common heritage of
humankind framework, namely: equitable sharing of
resources. This cardinal element is closely related to
benefit sharing [4]; it calls for an equal distribution of
resources and encourages global policies that foster a
homogeneous state of affairs among all states withrespect to common heritage resources. Developing
countries have envisaged this benefit sharing as a tool
that presents a solution to the disparities existing be-
tween developing and developed states [7]. Hence, it
has been advocated that the benefit sharing of the
common heritage of humankind should be extended
beyond the sharing of tangible resources to other pos-
sible goods [7]. For example, some scholars point out
that benefit sharing should also include the sharing of
technology with other states. This is based on the as-
sumption that technology is a common heritage of hu-
mankind because it is an inheritance of our ancestors
irrespective of their nationalities [8].
Notable international treaties that emphasize benefit
sharing in their common heritage of humankind regimes
include the United Nations Convention on Law of the Sea
(UNCLOS) and the International Undertaking on Plant
Genetic Resources (IUPGR). The UNCLOS stresses in
article 140 paragraph 1 the need to share benefits to
everyone irrespective of geographical location of states,
whether coastal or land-locked. The Convention also
indicates the need to particularly consider the vulner-
ability of developing states that may be at risk of exclu-
sion from benefit distribution [9]. Also, plant genetic
resources have been considered as part of the common
heritage of humankind [4,10]. This was indicated by
the agreement of International Undertaking on Plant
Genetic Resources (IUPGR). The agreement recognizes
that plant genetic resources are a heritage of human-
kind to be preserved, and to be freely available for use,
for the benefit of present and future generations [11].
The ethical appeal of benefit sharing in the common
heritage of humankind is targeted at achieving equality
among all states with regards to resource distribution.
The founder of the concept of common heritage of hu-
mankind, Arvid Pardo [12] clearly indicates this equality
in a statement that: “the common heritage of human-
kind challenges the structural differences between rich
and poor countries and revolutionizes international rela-
tions towards equality among countries” [13]. However,
the reality of achieving equality of resource distribution
remains problematic owing to the continuous power and
economic asymmetry that exists among states. Mounting
concern by developing countries about the uncompen-
sated use of plant genetic diversity obtained from their ter-
ritories pushed for a move against the common heritage
of humankind concept and an adoption of sovereign
rights to biodiversity [4]. It was argued that the com-
mon heritage of humankind and its benefit sharing re-
quirements would encourage exploitation and biopiracy—
a situation whereby bioprospectors travel to diversity rich
countries and take resources without seeking permission
or sharing benefits with host countries or local communi-
ties [14].
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genetic resources according to the Convention on
Biological Diversity (CBD)
The concept of benefit sharing has been concretized in
the context of the access and use of genetic resources
[15]. Genetic resources include both non human genetic
resources (e.g. plant, micro organism and animal genetic
resources) and human genetic resources (e.g. human
DNA material, blood and other human tissues). In this
context, benefit sharing denotes an exchange between
those who grant access to genetic resources and those
who provide benefits, rewards or compensations resulting
from the use of the genetic resources [1,14]. Unlike the
common heritage of humankind concept, in the context
of genetic resources, states hold a sovereign right over
their natural resources and can grant access to those that
require to utilize such resources under a condition of
Prior Informed Consent (PIC) and Mutually Agreed
Terms (MAT) of appropriate benefit sharing [16]. For ex-
ample, a local community in the Amazon region of South
America can negotiate a deal with plant scientists or
bioprospectors to exchange plant material expected to
have a medicinal property with medicinal products or roy-
alties that subsequently result from the utilization of the
plant material.
The concept of benefit sharing with regard to the use
of genetic resources originates from the CBD. The CBD
is said to mark the end of the era of the common heri-
tage of humankind concept. In the CBD preambles, re-
sources are deemed to be the “common concern”
instead of the “common heritage” of humankind. It is
the concern of all humankind to preserve and sustain
the use of resources for humanity and future genera-
tions. However, the duty to preserve and sustain re-
sources does not imply that resources are common
heritage for all; rather, resources are the property of the
states [10]. CBD declaration was first endorsed in 1992
however; the requirement of benefit sharing was fortified
through a series of discussions by the Conference of
Parties to the CBD which subsequently culminated
into a more emphatic framework known as the Nagoya
Protocol. The protocol which was adopted in 2010
provides a strong basis for greater legal certainty and
transparency for both providers and users of genetic
resources [17]. The legal certainties of the protocol re-
quire countries to develop laws to ensure that the use
of genetic resources within their jurisdiction is done
with prior informed consent and on mutually agreed
terms, and that it complies with benefit sharing legisla-
tion in other countries. While the transparency aspect
of the protocol require industrialized countries to set
up one or more checkpoints for disclosing what re-
sources they have accessed and where, and to monitor
whether they are complying with the protocol [17]. Ingeneral, the Nagoya Protocol addresses some critical
gaps and uncertainties in the CBD regulations on
benefit sharing and also sets in motion formal discus-
sions on other unresolved topics and ideas [18].
The concept of benefit sharing here can be related to
the ethical principle of justice in exchange or commuta-
tive justice. Justice in exchange demands that those who
use resources give back due reward to the providers or
custodians of the resources [19]. This type of justice has
been quoted in articles to be related to Aristotelian no-
tion of fairness in a transaction which holds that the in-
trinsic worth of something has to be matched by a
proportionate requital either in kind or in pecuniary
terms [4,19]. While the ABS structure works for non-
human genetic resources, human genetic resources
could not be retained within the framework of the CBD.
The Conference of Parties to CBD in 1995 excluded hu-
man genetic resources from the legal framework of its
promulgation [20].
Benefit sharing and international clinical research
International clinical research refers to a research involv-
ing human subjects that is organized and sponsored by
pharmaceutical industries, Contract Research Organiza-
tions (CROs) and other research organizations in indus-
trialized countries but conducted or outsourced in
resource poor countries [21]. International clinical re-
search can be clinical trials of new drugs, testing of new
diagnostic equipment or genetic research that involves
the collection and storage of various genetic samples
e.g. Genome Wide Association Studies. Outsourcing
of research by pharmaceutical industries has been on
the rise and is mainly due to the ease of patient re-
cruitment, low overall cost of trial and relatively less
stringent regulatory procedures in the outsourced
countries. These reasons raise concerns on how to con-
duct research that is ethical in resource poor countries
[21,22]. Benefit sharing is considered to be one of the im-
portant benchmarks for ethical research in developing
countries [23]. Also, the discourse on benefit sharing in
international research springs from the fact that large pro-
portion of the populations in developing countries lives in
poverty and cannot pay for their health care services. As
such, health research conducted in these resource poor
countries should uphold obligations of providing the ben-
efits of research in order to improve the healthcare ser-
vices of these countries [24].
In human genetic research, the predominant stance on
benefit sharing suggests a return to the concept of the
common heritage of humankind. This is evident from
the emphasis on an equal sharing of the benefits arising
from human genetic resources to all of humanity. The
conjecture in human genetic research is that human be-
ings share 99.9% of their genome; as such, human genes
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of humankind, and all humans ought to share the col-
lective duty to explore their genetic resources, preserve
them and share equally the benefits derived from their
utilization. This position was declared by the United Na-
tions Educational, Scientific and Cultural Organization
(UNESCO) Declaration on Human Genome and Human
Rights (1997) and followed by the Human Genome
Organization (HUGO) Committee on Ethics (2000). The
main ethical disposition regarding benefit sharing in hu-
man genetic research is centered on solidarity, whereby
everyone (not only the research participants) is entitled
to the benefits derived from advances in genetic re-
search. This is evident in the UNESCO declaration
which states that “benefits from advances in biology,
genetics and medicine, concerning the human genome,
shall be made available to all” [25]. To demonstrate the
need for commitment to support developing countries
through benefit sharing, the HUGO ethics committee
proposed that 1-3% of the profits gained by research or-
ganizations should be set aside for charitable work in de-
veloping countries. Setting this figure was intended to
provide a minimum requirement that would encourage
companies to be good universal citizens [26].
Furthermore, benefit sharing in international research
is viewed in three perspectives. Firstly, benefit sharing is
viewed as the provision of post-research results of the
proven intervention. In other words, when the interven-
tion tested in research has shown to be effective, it
should be made “reasonably available” to the host com-
munity. This so-called “reasonable availability” in re-
search emerged during the debate on the standard of
care to be accorded to research participants in develop-
ing countries [27]. Reasonable availability requires that
research be tailored to the health needs of the host com-
munity and the research results be made available to the
community at the end of the research [28,29]. This re-
quirement is found in international ethical guidelines for
the conduct of research. For example, the Helsinki dec-
laration states in paragraph 33 that, “at the conclusion of
the study, patients entered into the study are entitled to
be informed about the outcome of the study and to
share any benefits that result from it, for example, access
to interventions identified as beneficial in the study or to
other appropriate care or benefits” [30]. It is noteworthy
to know that a new draft of the Helsinki declaration is
formulated and is geared towards a development of a
new version of the Helsinki Declaration—the draft has a
recommendation for amendments on the wordings of
reasonable availability and benefit sharing [31].
Reasonable availability can be seen in the light of justice
as reciprocity. It is concerned with what people deserve as
a function of what they have contributed to an enterprise
or the society. In clinical research, justice as reciprocitymeans that something is owed to the research participants
and the community even after their participation in a trial
has ended, because it is only through their acceptance of
risk and inconvenience that researchers are able to gener-
ate findings necessary to advance knowledge and develop
new medical interventions [32].
Secondly, benefit sharing in international research is
viewed through the lens of the fair benefit approach,
whereby the research community and research sponsors
enter into a bargain in order to derive what is appropri-
ate and fair benefit(s) that the participants should accrue
[33]. The fair benefit approach argues for proportionality
of benefits with regard to the risks and burdens of par-
ticipation in research. The higher the risk of participa-
tion in research, the higher the benefit accrued ought to
be. The approach also delineates that fairness of benefit
is concerned with how much benefit is given to the par-
ticipants or community, not what type of benefit they
accrue as in the case of reasonable availability [33]. The
fundamental difference between the reasonable availabil-
ity and fair benefit approaches is that while the former
restricts benefits to the proven intervention only, the
latter expands the range of benefits to other possible
benefits besides the proven intervention. This differ-
ence is echoed by the Participants at the Conference
on Ethical Aspects of Research: post-research interven-
tion is one way to provide benefits to the community
but not the only way, and it must not be considered a
necessary ethical condition for research in developing
countries [34].
Thirdly, benefit sharing can be viewed according to
the maximin approach. Maximin places benefit sharing
in a broader concept of global distributive justice and
depart from the view that negotiating activities between
parties (sponsors and participants or communities)
should always favor the disadvantaged group in their
benefit sharing formulations [35]. The maximin ap-
proach is suitable considering the marked power and
economic asymmetry between research sponsors and the
vulnerable research community. Such asymmetry makes
the vulnerable population view research as an opportunity
to access better healthcare or to improve their health con-
ditions. As a result, research communities in developing
countries that strive to access basic goods (e.g. healthcare)
during research should be assured of some benefits in the
spirit of global distributive justice for basic goods
[27,36]. With regard to the fairness of benefit sharing,
the maximin approach suggests that a threshold of
benefits should be set, beyond which it would no lon-
ger be rational for a self-interested research sponsor to
transact [35]. In more practical terms, maximin advo-
cates that pharmaceutical industries that outsource re-
search to poor communities provide the best deal of
benefits so that the poor accrue more benefits from
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in the poor community.
The main emphasis in the maximin approach is on
benefits on a macro level—i.e. benefits that will improve
the overall healthcare structures of the poor communi-
ties. This is in contrast to the fair benefit approach
which relies on the procedural bargaining powers of the
parties involved in the transaction [35]. The maximin
approach is seen as a way in which general improvement
in healthcare as a basic good can be obtained through
research, and consequently the gap of health-related
inequality between the rich and poor can be bridged.
Furthermore, the maximin approach has a positive advan-
tage in that it provides benefit to the community irre-
spective of whether a post-research product is developed
or not from the research [37].
Ethical and legal changes on benefit sharing
From the foregoing discussion, it is clear that benefit
sharing has undergone ethical and legal changes from its
inception in the common heritage of humankind con-
cept to its usage in international research (Table 1). Re-
garding the ethical changes, we can ascertain that the
main ethical justification of benefit sharing changes in
each context. In the context of the common heritage of
humankind, benefit sharing is justified based on the
principle of justice as equality whereby everyone de-
serves the same dignity, respect and moral worth [38].
Justice as equality entitles every state as a matter of
rights to the benefits derived from the common heritage
of humankind and it would be unjust not to share
equally the benefits arising from the utilization of these
common heritage resources. This ethical disposition has
changed in the premise of the CBD. The justification of
benefit sharing in the CBD is fundamentally based on
the principle of justice in exchange or commutative just-
ice. This exchange is between states that provide genetic
resources on the one hand and states that access/utilize
such resources on the other hand. Justice in exchangeTable 1 Benefit sharing disposition in various contexts
Context of benefit sharing Main ethical justification Parties in
Common Heritage of
Humankind
Justice as equality All states o
Convention on Biological
Diversity












Solidarity (Genetic research)demands that fairness is ensured in what is exchanged
when states interact with each other [39]. Therefore it
would be unjust for a state not to provide fair and equit-
able benefit for an exchange of plant or micro-organism
genetic material given to her.
In the context of international research, there are four
major justifications that benefit sharing is based on.
Firstly, taking on the discourse of human genetic re-
search, benefit sharing is justified on solidarity reasons
whereby participants, communities and other popula-
tions outside the research setting have the right to bene-
fits from the fruits of the research. In other words,
benefit sharing is a gesture of solidarity between re-
search sponsors on the one hand and participants, com-
munities and in extension other populations on the
other hand. As participants contribute their genes for re-
search in solidarity, sponsors should return back this
solidarity by distributing benefits to participants and
everyone [40]. Secondly, justice as reciprocity also pro-
vides a justification for benefit sharing in international
research considering the “reasonable availability” view-
point. Participants’ contributions are reciprocated with
products generated from research for their efforts, time
and risks taken in research [33]. Thirdly, benefit sharing
is also justified on the basis of procedural justice in
international research. This is mainly seen in the fair
benefit approach model [34]. Procedural justice is con-
sidered to be the main ethical disposition in the fair ben-
efits approach because the approach emphasizes that
fairness on benefit sharing is achieved when research
participants and communities enter into a bargain or ne-
gotiation with the research sponsors in order to achieve
fairness on benefit sharing—and the processes of negoti-
ation or bargain must be made transparent to all. In
other words as long as the negotiations between re-
search sponsors and communities are transparent and
the parties involved have reach an agreement, then the
benefit sharing is said to be fair [34]. Fourthly, based on
the maximin approach, benefit sharing is justified on thevolved in benefit sharing Legal stance of benefit sharing
regulations
f the universe Binding regulations (e.g. UNCLOS 1982,
IUPGR 1983)
t provide genetic resources Binding regulations on states that ratified
the CBDt utilize genetic resources
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inequalities between research communities and research
sponsors form the main reason for benefit sharing. On
the basis of this health inequality, global justice demands
that research benefits should not only target the small
needs of the research community but also the large
needs of basic healthcare of the community and strive
for improved health systems [41]. In summary we can
say that the main ethical justification of benefit sharing
has changed from justice as equality in a concept of the
common heritage of humankind to justice in exchange
in the CBD and to four major justifications in the con-
text of international research.
With regard to legal changes, benefit sharing has
undergone a shift in terms of its force and protection
under the law (Table 1). Under the common heritage of
humankind concept, the concept of benefit sharing ex-
erts protection as it is enshrined under a legally binding
agreement. States that endorse the common heritage of
humankind law have to agree with its accompanied
benefit sharing regulation. This also applies to the CBD
regulation on the use of non-human genetic resources.
The CBD is even more stringent as it has a separate
binding agreement on benefit sharing (Nagoya Protocol)
which legally regulates non human genetic resources.
However, with regard to the use of human genetic re-
sources and in international research the protection of
benefit sharing by a binding document is absent. This
represents a shift away from a concept that is protected
by law to a non binding regulation as documented in the
UNESCO Declaration on the Human Genome and Human
Rights (1997), the HUGO Ethics Committee statement on
benefit sharing (2000), the UNESCO Declaration on
Bioethics and Human Rights (2005) and the Helsinki Dec-
laration of the World Medical Association (WMA, 2008).
The question of importance hitherto is: do the changes
in the ethical and legal stance on benefit sharing in inter-
national research affect the present practice of benefit
sharing in international research? One can consistently
hold the view that making a certain regulation into law
gives it supremacy and makes it firm in terms of imple-
mentation among states [42]. In other words, regulations
that are passed into law are meant to be taken seriously
and states are obliged to abide to the regulations whether
they suit their intentions or not. The law therefore is al-
ways devised to enforce a duty without consideration of
individual choices. We can also assert that some laws are
formulated from certain ethical features that are deemed
fundamental to societal living and human co-existence.
For example, the rich biodiversity in developing countries
is important to human existence—the need to protect and
sustain its utilization for future generation is of immense
significance, hence the CBD law created to protect against
uncontrolled use and biopiracy of the biodiversity [19]. Itgoes without saying that if benefit sharing in international
research is to be taken seriously as a vital substance of glo-
bal health research, then its regulations must be enshrined
into a legally binding framework. The absence of a legally
binding document to regulate benefit sharing in inter-
national research has undoubtedly affected the tenacity of
its advocacy in practice.
Summary
Based on the account of the ethico-legal changes, we
suggest that benefit sharing in international research be
formulated into a legal framework, as this will under-
score the need to take it more seriously. Benefit sharing
should be formulated in such a way that the level of
benefits accrued from research participation is corres-
pondingly matched with certain parameters such as the
type of research in question, the organization sponsoring
the research, the purpose of the research etc. In other
words, a map of different possible types of research
should be made and this should be matched with mini-
mum forms of possible benefits that correspond to the
research in question. The research sponsors can provide
more than this minimum form of possible benefits if
they are willing, however the minimum standard of bene-
fits are obligatory by law. For example, a sponsor collabor-
ating in a malaria vaccine research with a community
should provide a range of benefits—for instance, environ-
mental fumigation services, distribution of insecticide-
treated nets to members of the community, effective
malaria treatments for participants that may develop
malaria during research etc. This range of benefits
would be considered to be the minimum standard that
must be provided to the collaborating community. The
collaborating research community can negotiate with
the research sponsors for other forms of benefits they
may prefer. All the procedures and agreements on re-
search benefits between the sponsor and community
must be properly documented and be legally binding.
This legal framework is necessary because benefit shar-
ing is mostly ignored even though it is regarded as an
ethically sound concept in international research [43].
The legal framework will ensure that international re-
search actors abide at all times to the set legal require-
ments of benefits whenever they interact with research
communities. Furthermore, because benefits will be
linked to legal promulgation, the local research com-
munity will be encouraged to collaborate and be more
open in research because they are certain of benefiting
from the fruits of research. A legal framework of bene-
fit sharing will dispel the issue of mistrust between re-
search sponsors and host states or communities where
research is done. An example of such mistrust is seen
in the recent case of the Indonesian government’s re-
fusal to provide H5N1 samples from its citizens to the
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ment on the grounds that they are not sure if the bene-
fits of such a vaccine would be shared fairly with the
Indonesian people [44].
While we hold the view that a non binding stance of
benefit sharing affects its current standing in inter-
national research, we do not believe that the multiple
ethical justifications in international research have also
affected the stance of benefit sharing. The multiple justi-
fications provide different ethical platforms on which the
normative bearings of benefit sharing can be ascertained.
As such, the multiple justifications only provide different
pathways to benefit sharing formulations and do not
weaken the normative ethical appeal of the concept, as
Simms rightly puts: “the existence of various arguments
[justifications] behind benefit sharing is not necessarily
problematic in itself […] the justifications can however
produce different benefit sharing rationale” [3].
We must affirm however, that while a legal framework
of benefit sharing in international research would aug-
ment its practice, the ease of formulating such a frame-
work is not a simple task. More research is needed in
order to determine factors that will facilitate creating a
benefit sharing law in international research. Research is
needed to establish lessons from the enactment of CBD
laws that will foster the development of a legal benefit
sharing framework in international research. There is a
need to critically ascertain other international legal frame-
works that directly or indirectly affect the practice of
benefit sharing e.g. the Intellectual Property Laws. Re-
searches on different contexts, various stakeholders as well
as the complexities of international research are needed to
establish different forms of benefit sharing formulations
that are feasible. Different benefit sharing formulations
can be related to the type of research in question. This will
help in establishing fairness of benefit with regard to the
risk of research. Also, more justifications and motivations
for benefit sharing among international research sponsors
need to be investigated.
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